Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing sched...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Guo, Christina [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
|---|---|
| Übergeordnetes Werk: |
volume:21 ; year:2020 ; number:11 ; pages:1478-1488 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1470-2045(20)30464-2 |
|---|
| Katalog-ID: |
ELV051917106 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV051917106 | ||
| 003 | DE-627 | ||
| 005 | 20230624181440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(20)30464-2 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001529.pica |
| 035 | |a (DE-627)ELV051917106 | ||
| 035 | |a (ELSEVIER)S1470-2045(20)30464-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 35.70 |2 bkl | ||
| 084 | |a 42.12 |2 bkl | ||
| 100 | 1 | |a Guo, Christina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study |
| 264 | 1 | |c 2020 | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. | ||
| 700 | 1 | |a Chénard-Poirier, Maxime |4 oth | |
| 700 | 1 | |a Roda, Desamparados |4 oth | |
| 700 | 1 | |a de Miguel, Maria |4 oth | |
| 700 | 1 | |a Harris, Samuel J |4 oth | |
| 700 | 1 | |a Candilejo, Irene Moreno |4 oth | |
| 700 | 1 | |a Sriskandarajah, Priya |4 oth | |
| 700 | 1 | |a Xu, Wen |4 oth | |
| 700 | 1 | |a Scaranti, Mariana |4 oth | |
| 700 | 1 | |a Constantinidou, Anastasia |4 oth | |
| 700 | 1 | |a King, Jenny |4 oth | |
| 700 | 1 | |a Parmar, Mona |4 oth | |
| 700 | 1 | |a Turner, Alison J |4 oth | |
| 700 | 1 | |a Carreira, Suzanne |4 oth | |
| 700 | 1 | |a Riisnaes, Ruth |4 oth | |
| 700 | 1 | |a Finneran, Laura |4 oth | |
| 700 | 1 | |a Hall, Emma |4 oth | |
| 700 | 1 | |a Ishikawa, Yuji |4 oth | |
| 700 | 1 | |a Nakai, Kiyohiko |4 oth | |
| 700 | 1 | |a Tunariu, Nina |4 oth | |
| 700 | 1 | |a Basu, Bristi |4 oth | |
| 700 | 1 | |a Kaiser, Martin |4 oth | |
| 700 | 1 | |a Lopez, Juanita Suzanne |4 oth | |
| 700 | 1 | |a Minchom, Anna |4 oth | |
| 700 | 1 | |a de Bono, Johann S |4 oth | |
| 700 | 1 | |a Banerji, Udai |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:11 |g pages:1478-1488 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(20)30464-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
| 936 | b | k | |a 42.12 |j Biophysik |q VZ |
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 11 |h 1478-1488 |g 11 | ||
| author_variant |
c g cg |
|---|---|
| matchkey_str |
guochristinachnardpoiriermaximerodadesam:2020----:nemtetceueoterlamkniioc5276s76nainsiharfuatoitmusnmlilmeoasnlcnroelbl |
| hierarchy_sort_str |
2020 |
| bklnumber |
35.70 42.12 |
| publishDate |
2020 |
| allfields |
10.1016/S1470-2045(20)30464-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001529.pica (DE-627)ELV051917106 (ELSEVIER)S1470-2045(20)30464-2 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Guo, Christina verfasserin aut Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study 2020 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. Chénard-Poirier, Maxime oth Roda, Desamparados oth de Miguel, Maria oth Harris, Samuel J oth Candilejo, Irene Moreno oth Sriskandarajah, Priya oth Xu, Wen oth Scaranti, Mariana oth Constantinidou, Anastasia oth King, Jenny oth Parmar, Mona oth Turner, Alison J oth Carreira, Suzanne oth Riisnaes, Ruth oth Finneran, Laura oth Hall, Emma oth Ishikawa, Yuji oth Nakai, Kiyohiko oth Tunariu, Nina oth Basu, Bristi oth Kaiser, Martin oth Lopez, Juanita Suzanne oth Minchom, Anna oth de Bono, Johann S oth Banerji, Udai oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:21 year:2020 number:11 pages:1478-1488 extent:11 https://doi.org/10.1016/S1470-2045(20)30464-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 21 2020 11 1478-1488 11 |
| spelling |
10.1016/S1470-2045(20)30464-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001529.pica (DE-627)ELV051917106 (ELSEVIER)S1470-2045(20)30464-2 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Guo, Christina verfasserin aut Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study 2020 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. Chénard-Poirier, Maxime oth Roda, Desamparados oth de Miguel, Maria oth Harris, Samuel J oth Candilejo, Irene Moreno oth Sriskandarajah, Priya oth Xu, Wen oth Scaranti, Mariana oth Constantinidou, Anastasia oth King, Jenny oth Parmar, Mona oth Turner, Alison J oth Carreira, Suzanne oth Riisnaes, Ruth oth Finneran, Laura oth Hall, Emma oth Ishikawa, Yuji oth Nakai, Kiyohiko oth Tunariu, Nina oth Basu, Bristi oth Kaiser, Martin oth Lopez, Juanita Suzanne oth Minchom, Anna oth de Bono, Johann S oth Banerji, Udai oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:21 year:2020 number:11 pages:1478-1488 extent:11 https://doi.org/10.1016/S1470-2045(20)30464-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 21 2020 11 1478-1488 11 |
| allfields_unstemmed |
10.1016/S1470-2045(20)30464-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001529.pica (DE-627)ELV051917106 (ELSEVIER)S1470-2045(20)30464-2 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Guo, Christina verfasserin aut Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study 2020 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. Chénard-Poirier, Maxime oth Roda, Desamparados oth de Miguel, Maria oth Harris, Samuel J oth Candilejo, Irene Moreno oth Sriskandarajah, Priya oth Xu, Wen oth Scaranti, Mariana oth Constantinidou, Anastasia oth King, Jenny oth Parmar, Mona oth Turner, Alison J oth Carreira, Suzanne oth Riisnaes, Ruth oth Finneran, Laura oth Hall, Emma oth Ishikawa, Yuji oth Nakai, Kiyohiko oth Tunariu, Nina oth Basu, Bristi oth Kaiser, Martin oth Lopez, Juanita Suzanne oth Minchom, Anna oth de Bono, Johann S oth Banerji, Udai oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:21 year:2020 number:11 pages:1478-1488 extent:11 https://doi.org/10.1016/S1470-2045(20)30464-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 21 2020 11 1478-1488 11 |
| allfieldsGer |
10.1016/S1470-2045(20)30464-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001529.pica (DE-627)ELV051917106 (ELSEVIER)S1470-2045(20)30464-2 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Guo, Christina verfasserin aut Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study 2020 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. Chénard-Poirier, Maxime oth Roda, Desamparados oth de Miguel, Maria oth Harris, Samuel J oth Candilejo, Irene Moreno oth Sriskandarajah, Priya oth Xu, Wen oth Scaranti, Mariana oth Constantinidou, Anastasia oth King, Jenny oth Parmar, Mona oth Turner, Alison J oth Carreira, Suzanne oth Riisnaes, Ruth oth Finneran, Laura oth Hall, Emma oth Ishikawa, Yuji oth Nakai, Kiyohiko oth Tunariu, Nina oth Basu, Bristi oth Kaiser, Martin oth Lopez, Juanita Suzanne oth Minchom, Anna oth de Bono, Johann S oth Banerji, Udai oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:21 year:2020 number:11 pages:1478-1488 extent:11 https://doi.org/10.1016/S1470-2045(20)30464-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 21 2020 11 1478-1488 11 |
| allfieldsSound |
10.1016/S1470-2045(20)30464-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001529.pica (DE-627)ELV051917106 (ELSEVIER)S1470-2045(20)30464-2 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Guo, Christina verfasserin aut Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study 2020 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. Chénard-Poirier, Maxime oth Roda, Desamparados oth de Miguel, Maria oth Harris, Samuel J oth Candilejo, Irene Moreno oth Sriskandarajah, Priya oth Xu, Wen oth Scaranti, Mariana oth Constantinidou, Anastasia oth King, Jenny oth Parmar, Mona oth Turner, Alison J oth Carreira, Suzanne oth Riisnaes, Ruth oth Finneran, Laura oth Hall, Emma oth Ishikawa, Yuji oth Nakai, Kiyohiko oth Tunariu, Nina oth Basu, Bristi oth Kaiser, Martin oth Lopez, Juanita Suzanne oth Minchom, Anna oth de Bono, Johann S oth Banerji, Udai oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:21 year:2020 number:11 pages:1478-1488 extent:11 https://doi.org/10.1016/S1470-2045(20)30464-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 21 2020 11 1478-1488 11 |
| language |
English |
| source |
Enthalten in My London volume:21 year:2020 number:11 pages:1478-1488 extent:11 |
| sourceStr |
Enthalten in My London volume:21 year:2020 number:11 pages:1478-1488 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Biochemie: Allgemeines Biophysik |
| institution |
findex.gbv.de |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
My |
| authorswithroles_txt_mv |
Guo, Christina @@aut@@ Chénard-Poirier, Maxime @@oth@@ Roda, Desamparados @@oth@@ de Miguel, Maria @@oth@@ Harris, Samuel J @@oth@@ Candilejo, Irene Moreno @@oth@@ Sriskandarajah, Priya @@oth@@ Xu, Wen @@oth@@ Scaranti, Mariana @@oth@@ Constantinidou, Anastasia @@oth@@ King, Jenny @@oth@@ Parmar, Mona @@oth@@ Turner, Alison J @@oth@@ Carreira, Suzanne @@oth@@ Riisnaes, Ruth @@oth@@ Finneran, Laura @@oth@@ Hall, Emma @@oth@@ Ishikawa, Yuji @@oth@@ Nakai, Kiyohiko @@oth@@ Tunariu, Nina @@oth@@ Basu, Bristi @@oth@@ Kaiser, Martin @@oth@@ Lopez, Juanita Suzanne @@oth@@ Minchom, Anna @@oth@@ de Bono, Johann S @@oth@@ Banerji, Udai @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003173852 |
| dewey-sort |
3570 |
| id |
ELV051917106 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV051917106</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624181440.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(20)30464-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001529.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV051917106</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(20)30464-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guo, Christina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chénard-Poirier, Maxime</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roda, Desamparados</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Miguel, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harris, Samuel J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Candilejo, Irene Moreno</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sriskandarajah, Priya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Wen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scaranti, Mariana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Constantinidou, Anastasia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">King, Jenny</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parmar, Mona</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turner, Alison J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carreira, Suzanne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riisnaes, Ruth</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Finneran, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hall, Emma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishikawa, Yuji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakai, Kiyohiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tunariu, Nina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Basu, Bristi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaiser, Martin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopez, Juanita Suzanne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Minchom, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Bono, Johann S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Banerji, Udai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1478-1488</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(20)30464-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2020</subfield><subfield code="e">11</subfield><subfield code="h">1478-1488</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| author |
Guo, Christina |
| spellingShingle |
Guo, Christina ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study |
| authorStr |
Guo, Christina |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study |
| topic |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_unstemmed |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_browse |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m c p mcp d r dr m m d mm mmd s j h sj sjh i m c im imc p s ps w x wx m s ms a c ac j k jk m p mp a j t aj ajt s c sc r r rr l f lf e h eh y i yi k n kn n t nt b b bb m k mk j s l js jsl a m am b j s d bjs bjsd u b ub |
| hierarchy_parent_title |
My |
| hierarchy_parent_id |
ELV003173852 |
| dewey-tens |
570 - Life sciences; biology |
| hierarchy_top_title |
My |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003173852 |
| title |
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study |
| ctrlnum |
(DE-627)ELV051917106 (ELSEVIER)S1470-2045(20)30464-2 |
| title_full |
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study |
| author_sort |
Guo, Christina |
| journal |
My |
| journalStr |
My |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
1478 |
| author_browse |
Guo, Christina |
| container_volume |
21 |
| physical |
11 |
| class |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Guo, Christina |
| doi_str_mv |
10.1016/S1470-2045(20)30464-2 |
| dewey-full |
570 |
| title_sort |
intermittent schedules of the oral raf–mek inhibitor ch5126766/vs-6766 in patients with ras/raf-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study |
| title_auth |
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study |
| abstract |
CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. |
| abstractGer |
CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. |
| abstract_unstemmed |
CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
11 |
| title_short |
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study |
| url |
https://doi.org/10.1016/S1470-2045(20)30464-2 |
| remote_bool |
true |
| author2 |
Chénard-Poirier, Maxime Roda, Desamparados de Miguel, Maria Harris, Samuel J Candilejo, Irene Moreno Sriskandarajah, Priya Xu, Wen Scaranti, Mariana Constantinidou, Anastasia King, Jenny Parmar, Mona Turner, Alison J Carreira, Suzanne Riisnaes, Ruth Finneran, Laura Hall, Emma Ishikawa, Yuji Nakai, Kiyohiko Tunariu, Nina Basu, Bristi Kaiser, Martin Lopez, Juanita Suzanne Minchom, Anna de Bono, Johann S Banerji, Udai |
| author2Str |
Chénard-Poirier, Maxime Roda, Desamparados de Miguel, Maria Harris, Samuel J Candilejo, Irene Moreno Sriskandarajah, Priya Xu, Wen Scaranti, Mariana Constantinidou, Anastasia King, Jenny Parmar, Mona Turner, Alison J Carreira, Suzanne Riisnaes, Ruth Finneran, Laura Hall, Emma Ishikawa, Yuji Nakai, Kiyohiko Tunariu, Nina Basu, Bristi Kaiser, Martin Lopez, Juanita Suzanne Minchom, Anna de Bono, Johann S Banerji, Udai |
| ppnlink |
ELV003173852 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1470-2045(20)30464-2 |
| up_date |
2024-07-06T21:35:34.759Z |
| _version_ |
1803867111827701760 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV051917106</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624181440.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(20)30464-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001529.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV051917106</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(20)30464-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guo, Christina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS–RAF–MEK pathway mutations.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chénard-Poirier, Maxime</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roda, Desamparados</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Miguel, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harris, Samuel J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Candilejo, Irene Moreno</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sriskandarajah, Priya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Wen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scaranti, Mariana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Constantinidou, Anastasia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">King, Jenny</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parmar, Mona</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turner, Alison J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carreira, Suzanne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riisnaes, Ruth</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Finneran, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hall, Emma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishikawa, Yuji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakai, Kiyohiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tunariu, Nina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Basu, Bristi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaiser, Martin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopez, Juanita Suzanne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Minchom, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Bono, Johann S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Banerji, Udai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1478-1488</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(20)30464-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2020</subfield><subfield code="e">11</subfield><subfield code="h">1478-1488</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| score |
7.400958 |